SG11202005281XA - Gene editing using a modified closed-ended dna (cedna) - Google Patents

Gene editing using a modified closed-ended dna (cedna)

Info

Publication number
SG11202005281XA
SG11202005281XA SG11202005281XA SG11202005281XA SG11202005281XA SG 11202005281X A SG11202005281X A SG 11202005281XA SG 11202005281X A SG11202005281X A SG 11202005281XA SG 11202005281X A SG11202005281X A SG 11202005281XA SG 11202005281X A SG11202005281X A SG 11202005281XA
Authority
SG
Singapore
Prior art keywords
cedna
gene editing
ended dna
modified closed
modified
Prior art date
Application number
SG11202005281XA
Inventor
Robert M Kotin
Douglas Kerr
Phillip Samayoa
Ozan Alkan
Matthew J Simmons
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of SG11202005281XA publication Critical patent/SG11202005281XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202005281XA 2017-12-06 2018-12-06 Gene editing using a modified closed-ended dna (cedna) SG11202005281XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762595328P 2017-12-06 2017-12-06
US201762607069P 2017-12-18 2017-12-18
PCT/US2018/064242 WO2019113310A1 (en) 2017-12-06 2018-12-06 Gene editing using a modified closed-ended dna (cedna)

Publications (1)

Publication Number Publication Date
SG11202005281XA true SG11202005281XA (en) 2020-07-29

Family

ID=66751200

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11202005281XA SG11202005281XA (en) 2017-12-06 2018-12-06 Gene editing using a modified closed-ended dna (cedna)
SG10202012132WA SG10202012132WA (en) 2017-12-06 2018-12-06 Gene editing using a modified closed-ended dna (cedna)

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202012132WA SG10202012132WA (en) 2017-12-06 2018-12-06 Gene editing using a modified closed-ended dna (cedna)

Country Status (14)

Country Link
US (1) US20220290186A1 (en)
EP (1) EP3720952A4 (en)
JP (2) JP2021505159A (en)
KR (1) KR20200093635A (en)
CN (1) CN111527200A (en)
AU (1) AU2018378672A1 (en)
BR (1) BR112020009858A2 (en)
CA (1) CA3084185A1 (en)
IL (1) IL274845A (en)
MA (1) MA51113A (en)
MX (1) MX2020005808A (en)
PH (1) PH12020550771A1 (en)
SG (2) SG11202005281XA (en)
WO (1) WO2019113310A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
EP3092049A1 (en) 2014-01-08 2016-11-16 Flodesign Sonics Inc. Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US20200263204A1 (en) * 2017-09-28 2020-08-20 Toolgen Incorporated Composition for treating hemophilia a by crispr/cas system of reverting fviii gene inversion
MX2020008470A (en) * 2018-02-14 2020-09-25 Generation Bio Co Non-viral dna vectors and uses thereof for antibody and fusion protein production.
CN109022389A (en) * 2018-07-19 2018-12-18 陕西慧康生物科技有限责任公司 A kind of production method of Bacillus coli expression people Iduronate-2-sulfatase
AU2020289581A1 (en) 2019-06-07 2021-11-18 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized albumin locus
EP4022074A4 (en) * 2019-08-27 2023-11-15 The Trustees of Columbia University in the City of New York Engineered exosomes for targeted delivery
US20220275400A1 (en) * 2019-08-30 2022-09-01 The Trustees Of Columbia University In The City Of New York Methods for scalable gene insertions
KR20230003477A (en) * 2020-03-24 2023-01-06 제너레이션 바이오 컴퍼니 Non-viral DNA vectors and their use for expressing Factor IX therapeutics
US20210355506A1 (en) * 2020-05-13 2021-11-18 Lysogene Compositions and methods for treating gm1 gangliosidosis and other disorders
WO2022015856A1 (en) * 2020-07-14 2022-01-20 The Regents Of The University Of California Compositions and methods for treating an inherited retinal disease
EP4189098A1 (en) 2020-07-27 2023-06-07 Anjarium Biosciences AG Compositions of dna molecules, methods of making therefor, and methods of use thereof
KR20230066453A (en) * 2020-09-16 2023-05-15 제너레이션 바이오 컴퍼니 Non-viral DNA vectors and their use for expressing FVIII therapeutics
JP2023543291A (en) 2020-09-29 2023-10-13 アルベルト－ルドビクス－ウニベルジテート フライブルク Rescue of recombinant adenovirus by CRISPR/CAS-mediated in vivo end separation
CN112481262B (en) * 2020-12-04 2022-08-19 中国农业科学院农业基因组研究所 Method for analyzing biological functions of enhancer cells based on CRISPR/Cas9 gene editing technology
CN112852880B (en) * 2021-01-28 2022-12-06 中吉智药(南京)生物技术有限公司 Method for producing AAV gene medicine based on induced insect cell
AU2022237643A1 (en) * 2021-03-19 2023-09-28 Generation Bio Co. Non-viral dna vectors and uses thereof for expressing pfic therapeutics
EP4330416A1 (en) * 2021-04-26 2024-03-06 University of Massachusetts Direct raav-mediated in vivo gene editing of hematopoietic stem cells
EP4337177A1 (en) * 2021-05-11 2024-03-20 Modernatx, Inc. Non-viral delivery of dna for prolonged polypeptide expression in vivo
AU2022280952A1 (en) * 2021-05-28 2023-11-23 Beam Therapeutics Inc. Compositions and methods for the self-inactivation of base editors
WO2023283420A2 (en) * 2021-07-09 2023-01-12 The Board Of Trustees Of The University Of Illinois Therapeutic gene silencing with crispr-cas13
AR126846A1 (en) * 2021-08-23 2023-11-22 Bioverativ Therapeutics Inc OPTIMIZED FACTOR VIII GENES
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof
WO2024059699A2 (en) * 2022-09-16 2024-03-21 Joseph Fenton Lawler Trans-splicing methods and compositions for generation of single sex offspring

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2500434A1 (en) * 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
JP2016518142A (en) * 2013-05-10 2016-06-23 サンガモ バイオサイエンシーズ， インコーポレイテッド Delivery methods and compositions for nuclease-mediated genomic gene manipulation
SG10201804976YA (en) * 2013-12-12 2018-07-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for Genome Editing
US20160369258A1 (en) * 2014-03-11 2016-12-22 University Of Washington Restricting nuclear protein to specific phases of the cell cycle
EP3274454B1 (en) * 2015-03-25 2021-08-25 Editas Medicine, Inc. Crispr/cas-related methods, compositions and components
WO2016205728A1 (en) * 2015-06-17 2016-12-22 Massachusetts Institute Of Technology Crispr mediated recording of cellular events
KR102336362B1 (en) * 2016-03-03 2021-12-08 보이저 테라퓨틱스, 인크. Closed-ended linear duplex DNA for non-viral gene delivery
WO2019051255A1 (en) * 2017-09-08 2019-03-14 Generation Bio Co. Modified closed-ended dna (cedna)

Also Published As

Publication number Publication date
IL274845A (en) 2020-07-30
JP2021505159A (en) 2021-02-18
MA51113A (en) 2020-10-14
PH12020550771A1 (en) 2021-05-10
SG10202012132WA (en) 2021-01-28
KR20200093635A (en) 2020-08-05
WO2019113310A1 (en) 2019-06-13
BR112020009858A2 (en) 2020-11-17
EP3720952A1 (en) 2020-10-14
RU2020121128A (en) 2022-01-11
EP3720952A4 (en) 2021-09-01
US20220290186A1 (en) 2022-09-15
CN111527200A (en) 2020-08-11
MX2020005808A (en) 2020-10-28
JP2024003220A (en) 2024-01-11
AU2018378672A1 (en) 2020-07-09
CA3084185A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
IL274845A (en) Gene editing using a modified closed-ended dna (cedna)
IL272797A (en) Modified closed-ended dna (cedna)
ZA201806544B (en) Closed-ended linear duplex dna for non-viral gene transfer
EP3294880A4 (en) Synthetic single guide rna for cas9-mediated gene editing
HK1254230A1 (en) Tat-induced crispr/endonuclease-based gene editing
EP3510151A4 (en) High-throughput precision genome editing
IL252556A0 (en) Nucleic acid constructs for genome editing
IL252386B (en) Targeted rna editing
HK1252755A1 (en) Engineered nucleic-acid targeting nucleic acids
HK1252166A1 (en) Methods for generating circular dna from circular rna
GB201613135D0 (en) Genome editing
SG11201706636PA (en) Single-cell nucleic acids for high-throughput studies
EP3152221A4 (en) Method for editing a genetic sequence
EP3294879A4 (en) Optimized gene editing utilizing a recombinant endonuclease system
EP3186375A4 (en) Novel cas9 proteins and guiding features for dna targeting and genome editing
EP3450569A4 (en) Dna amplification method
GB201506509D0 (en) Nuclease-mediated genome editing
EP3734294A4 (en) Method for extracting nucleic acid using cartridge
GB201418892D0 (en) DNA editing
HK1220223A1 (en) A method for dna amplification dna
SG11201808538QA (en) Trans-splicing rna (tsrna)
GB201907242D0 (en) Dna methods etc ii
EP3508587A4 (en) Dna sequencing method
ZA201904764B (en) A multi-epitope dna vaccine for heartwater
IL269600A (en) Method for high-throughput genomic dna extraction